Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer

International Journal of Molecular Sciences

Thorsten H. Ecke¹  Thomas-Alexander Vögeli²  Ronja Morsch²  Ehab Hammad²  Lancelot Seillier³  Philipp Heinrich Baldia³  Sophie Wucherpfennig³  Ruth Knüchel³  Nadine T. Gaisa³  Maria Angela Cassataro³  Michael Rose³  Angela Maurer³ 

[1] Department of Urology, Helios Clinic, 15526 Bad Saarow, Germany;Department of Urology, RWTH Aachen University, 52074 Aachen, Germany;Institute of Pathology, RWTH Aachen University, 52074 Aachen, Germany;

关键词: bladder cancer;    therapeutic target;    squamous-differentiated carcinoma;    adenocarcinoma;    urachal carcinoma;    small cell neuroendocrine carcinoma;   

DOI  :  10.3390/ijms222111547

来源: DOAJ

【 摘 要 】

Histologically, bladder cancer is a heterogeneous group comprising urothelial carcinoma (UC), squamous cell carcinoma, adenocarcinomas (ACs), urachal carcinomas (UrCs), and small cell neuroendocrine carcinomas (SCCs). However, all bladder cancers have been treated so far uniformly, and targeted therapy options are still limited. Thus, we aimed to determine the protein expression/molecular status of commonly used cancer targets (programmed cell death 1 ligand 1 (PD-L1), mismatch repair (MMR), androgen and estrogen receptors (AR/ER), Nectin-4, tumor-associated calcium signal transducer 2 (Tacstd2, Trop-2), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and fibroblast growth factor receptor 3 (FGFR3)) to give first insights into whether patients with SCC, AC/UrCs, and squamous-differentiated carcinomas (Sq-BLCA) of the bladder could be eligible for targeted therapies. In addition, for MMR-deficient tumors, microsatellite instability was analyzed. We completed our own data with molecular data from The Cancer Genome Atlas (TCGA). We present ratios for each drug and cumulative ratios for multiple therapeutic options for each nonurothelial subtype. For example, 58.9% of SCC patients, 33.5% of AC/UrCs patients, and 79.3% of Sq-BLCA patients would be eligible for at least one of the analyzed targets. In conclusion, our findings hold promise for targeted therapeutic approaches in selected patients in the future, as various drugs could be applied according to the biomarker status.

【 授权许可】

Unknown